GlobeNewswire: Medeor Therapeutics Contains the last 10 of 1 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T23:40:04ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/04/28/974311/0/en/Medeor-Therapeutics-Receives-FDA-Clearance-of-IND-Application-and-Special-Protocol-Assessment-for-Pivotal-Clinical-Study-of-MDR-101.html?f=22&fvtc=4&fvtv=33150Medeor Therapeutics Receives FDA Clearance of IND Application and Special Protocol Assessment for Pivotal Clinical Study of MDR-1012017-04-28T11:30:00Z<![CDATA[Personalized cellular immunotherapy designed to prevent transplant kidney rejection and eliminate the need for chronic anti-rejection drugs]]>